gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1298Research ArticleГЕПАТОЛОГИЯHEPATOLOGYЛекарственные поражения печени (Часть 1-я)Drug-induced liver injuries (Part 1)ГалимоваС. Ф.GalimovaS. F.ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздравсоцразвития РФРоссияState educational government-financed institution of higher professional education «Sechenov First Moscow state medical university» Ministry of Health and Social Development of RussiaRussian Federation2012260620122233848Copyright © Галимова С.Ф., 20122012Галимова С.Ф.Galimova S.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1298

Цель обзора. Осветить современные представления о механизмах лекарственного поражения печени (ЛПП), дать их классификацию, представить подходы к диагностике заболевания.Основные положения. ЛПП могут протекать под маской всех известных острых и хронических заболеваний печени. Лекарства выступают одной из ведущих причин развития фульминантной печеночной недостаточности во многих странах мира. Ранняя диагностика и своевременная отмена препарата, вызывающего повреждение печени, позволяют предотвратить прогрессирование заболевания. В основе диагностики ЛПП лежит тщательный сбор лекарственного анамнеза, исключение других возможных причин поражения печени и применение диагностических шкал (CIOMS/RUCAM).Заключение. Лекарственные поражения занимают значительное место в большом спектре заболеваний печени, своевременная диагностика этих поражений дает возможность исключить прием соответствующих препаратов.

The aim of review

The aim of review. To present modern concepts on mechanisms of drug-induced liver injury (DILI), to give their classification, to present approaches to disease diagnostics.

Original positions

Original positions. DILI can progress under the mask of all known acute and chronic liver diseases. Pharmaceuticals act as one of the leading causes of development of fulminant liver failure in many countries of the world. Early diagnostics and well-timed cancellation of the drug causing liver damage, allow to prevent disease progression. Careful collection of medicinal past history, ruling out of other possible causes of liver injury and application of diagnostic scales (CIOMS/ RUCAM) lays in a basis of DILI diagnostics.

Conclusion

Conclusion. Drug-induced lesions occupies significant place in major spectrum of liver diseases, welltimed diagnostics of these lesions enables to exclude intake of the respective agents.

лекарственные поражения печенидиагностикалечениеdrug-induced liver injuriesdiagnosticstreatmentReferencesAndreytseva O.I., Zhuravel S.V., et al. Patient management in the waiting list for liver transplantation (potential recipients). Consil Medic. 2007; Suppl 2:66–70.Andreytseva O.I., Zhuravel S.V., et al. Patient management in the waiting list for liver transplantation (potential recipients). Consil Medic. 2007; Suppl 2:66–70.Ivashkin V.T. Liver disease and biliary tracts. М., 2005: 217–23.Ivashkin V.T. Liver disease and biliary tracts. М., 2005: 217–23.Andrade RJ, Lucena MI, Fernández MC, et al. Druginduced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005; 129:512–21.Andrade RJ, Lucena MI, Fernández MC, et al. Druginduced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005; 129:512–21.Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990; 11:272–6.Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990; 11:272–6.Björnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis.Björnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis.; 38:33–8.Гепатология 3, 2012; 38:33–8.Гепатология 3, 2012Blei AT, Larsen FS. Pathophysiology of cerebral edema in fulminant hepatic failure. J Hepatol. 1999; 31:771–6.Blei AT, Larsen FS. Pathophysiology of cerebral edema in fulminant hepatic failure. J Hepatol. 1999; 31:771–6.Chitturi S, Farrell GC. Drug-induced liver disease. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s diseases of the liver. 9th ed. Tokyo: Lippincott Williams & Wilkins, 2003:1059–127.Chitturi S, Farrell GC. Drug-induced liver disease. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s diseases of the liver. 9th ed. Tokyo: Lippincott Williams & Wilkins, 2003:1059–127.Clemmesen JO, Kondrup J, Ott P. Splanchnic and leg exchange of amino acids and ammonia in acute liver failure. Gastroenterology. 2000; 118:1131–9.Clemmesen JO, Kondrup J, Ott P. Splanchnic and leg exchange of amino acids and ammonia in acute liver failure. Gastroenterology. 2000; 118:1131–9.Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993; 46:1323–30.Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993; 46:1323–30.Davies D. Textbook of adverse drug reactions. Oxford [Oxfordshire]: Oxford University Press, 1985:18–45.Davies D. Textbook of adverse drug reactions. Oxford [Oxfordshire]: Oxford University Press, 1985:18–45.De Valle MB, Klinteberg AV, Alem N, et al. Druginduced liver injury in a Swedish University hospital outpatient hepatology clinic. Aliment Pharmacol Ther. 2006; 24:1187–95.De Valle MB, Klinteberg AV, Alem N, et al. Druginduced liver injury in a Swedish University hospital outpatient hepatology clinic. Aliment Pharmacol Ther. 2006; 24:1187–95.Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol. 2001; 14:611.Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol. 2001; 14:611.Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology. 2003; 37:924–30.Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology. 2003; 37:924–30.Hussaini SH, O’Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol. 2007; 19:15–20.Hussaini SH, O’Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol. 2007; 19:15–20.Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol. 2007; 102:2437–43.Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol. 2007; 102:2437–43.Lee BH, Koh WJ, Choi MS, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest. 2005; 127:1304–11.Lee BH, Koh WJ, Choi MS, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest. 2005; 127:1304–11.Lucena MI, Andrade RJ, Fernández MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006; 44:850–6.Lucena MI, Andrade RJ, Fernández MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006; 44:850–6.Maddrey WC. Drug-induced hepatotoxicity. J Clin Gastroenterol. 2005; 39:83–9.Maddrey WC. Drug-induced hepatotoxicity. J Clin Gastroenterol. 2005; 39:83–9.Navasa M, Garcia-Pagan JC, Bosch J, et al. Portal hypertensionin acute liver failure. Gut. 1992; 33, 965–8.Navasa M, Garcia-Pagan JC, Bosch J, et al. Portal hypertensionin acute liver failure. Gut. 1992; 33, 965–8.Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005; 41:1179–97.Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005; 41:1179–97.Riordan SM, Williams R. Mechanisms of hepatocyte injury, multiorgan failure, and prognostic criteria in acute liver failure. Semin Liver Dis. 2003; 23, 203–15.Riordan SM, Williams R. Mechanisms of hepatocyte injury, multiorgan failure, and prognostic criteria in acute liver failure. Semin Liver Dis. 2003; 23, 203–15.Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004; 10:1018–23.Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004; 10:1018–23.Scheuer PJ, Lefkowitch JH. Drug and toxins. In: Scheuer PJ, Lefkowitch JH, eds. Liver biopsy interpretation. 7th ed. Philadelphia: Elsevier Saunders, 2006:125–44.Scheuer PJ, Lefkowitch JH. Drug and toxins. In: Scheuer PJ, Lefkowitch JH, eds. Liver biopsy interpretation. 7th ed. Philadelphia: Elsevier Saunders, 2006:125–44.Shapiro MA, Lewis JH. Causality assessment of druginduced hepatotoxicity: promises and pitfalls. Clin Liver Dis. 2007; 11:477–505.Shapiro MA, Lewis JH. Causality assessment of druginduced hepatotoxicity: promises and pitfalls. Clin Liver Dis. 2007; 11:477–505.Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008; 14 (44):6774–85.Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008; 14 (44):6774–85.Textbook of Hepatology, From Basic Science to Clinical Practice. Third edition, sections 1–10 and index. Chapter 14.1. Drug-induced liver injury. Dominique Pessayre and Dominique Larrey:1211–77.Textbook of Hepatology, From Basic Science to Clinical Practice. Third edition, sections 1–10 and index. Chapter 14.1. Drug-induced liver injury. Dominique Pessayre and Dominique Larrey:1211–77.Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology. 2003; 125, 755–64.Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology. 2003; 125, 755–64.Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol. 2007; 102:558–62; quiz 693.Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol. 2007; 102:558–62; quiz 693.Wai CT, Tan BH, Chan CL, et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int. 2007; 27:465–74.Wai CT, Tan BH, Chan CL, et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int. 2007; 27:465–74.Watanabe M, Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japancomparison with two previous scales. Hepatol Res. 2004; 30:148–54.Watanabe M, Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japancomparison with two previous scales. Hepatol Res. 2004; 30:148–54.William M, Lee MD. Acetaminophen-Related Acute Liver Failure: ALFSG Update 2010. Acetaminophen Scientific Meeting, 2010 November 10.William M, Lee MD. Acetaminophen-Related Acute Liver Failure: ALFSG Update 2010. Acetaminophen Scientific Meeting, 2010 November 10.William M, Lee MD. Drug-Induced Hepatotoxicity. N Engl J Med. 2003; 349:474–85.William M, Lee MD. Drug-Induced Hepatotoxicity. N Engl J Med. 2003; 349:474–85.

The authors declare that there are no conflicts of interest present.